Expert opinion on drug metabolism & toxicology最新文献_第10页

Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine. 药代动力学的预测建模：从硅内模拟到个性化医疗。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-04-01 Epub Date: 2024-03-20 DOI: 10.1080/17425255.2024.2330666

Ajita Paliwal, Smita Jain, Sachin Kumar, Pranay Wal, Madhusmruti Khandai, Prasanna Shama Khandige, Vandana Sadananda, Md Khalid Anwer, Monica Gulati, Tapan Behl, Shriyansh Srivastava

{"title":"Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine.","authors":"Ajita Paliwal, Smita Jain, Sachin Kumar, Pranay Wal, Madhusmruti Khandai, Prasanna Shama Khandige, Vandana Sadananda, Md Khalid Anwer, Monica Gulati, Tapan Behl, Shriyansh Srivastava","doi":"10.1080/17425255.2024.2330666","DOIUrl":"10.1080/17425255.2024.2330666","url":null,"abstract":"Introduction: Pharmacokinetic parameters assessment is a critical aspect of drug discovery and development, yet challenges persist due to limited training data. Despite advancements in machine learning and in-silico predictions, scarcity of data hampers accurate prediction of drug candidates' pharmacokinetic properties.Areas covered: The study highlights current developments in human pharmacokinetic prediction, talks about attempts to apply synthetic approaches for molecular design, and searches several databases, including Scopus, PubMed, Web of Science, and Google Scholar. The article stresses importance of rigorous analysis of machine learning model performance in assessing progress and explores molecular modeling (MM) techniques, descriptors, and mathematical approaches. Transitioning to clinical drug development, article highlights AI (Artificial Intelligence) based computer models optimizing trial design, patient selection, dosing strategies, and biomarker identification. In-silico models, including molecular interactomes and virtual patients, predict drug performance across diverse profiles, underlining the need to align model results with clinical studies for reliability. Specialized training for human specialists in navigating predictive models is deemed critical. Pharmacogenomics, integral to personalized medicine, utilizes predictive modeling to anticipate patient responses, contributing to more efficient healthcare system. Challenges in realizing potential of predictive modeling, including ethical considerations and data privacy concerns, are acknowledged.Expert opinion: AI models are crucial in drug development, optimizing trials, patient selection, dosing, and biomarker identification and hold promise for streamlining clinical investigations.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"181-195"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140121637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients. 银屑病患者口服系统非生物疗法的临床药代动力学和药效学。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-04-01 Epub Date: 2024-03-28 DOI: 10.1080/17425255.2024.2335310

Justin M Eichinger, Divya M Shan, Jonathan D Greenzaid, Lisa Anakwenze, Steven R Feldman

{"title":"Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients.","authors":"Justin M Eichinger, Divya M Shan, Jonathan D Greenzaid, Lisa Anakwenze, Steven R Feldman","doi":"10.1080/17425255.2024.2335310","DOIUrl":"10.1080/17425255.2024.2335310","url":null,"abstract":"Introduction: Psoriasis is a chronic inflammatory immune condition. Treatments for psoriasis vary with disease severity, ranging from topicals to systemic biologic agents. The pharmacokinetic (PK) and pharmacodynamic (PD) properties of these therapies establish drug efficacy, toxicity, and optimal dosing to ensure therapeutic drug levels are sustained and adverse effects are minimized.Areas covered: A literature search was performed on PubMed, Google Scholar, and Ovid MEDLINE for PK and PD, efficacy, and safety data regarding oral systemic nonbiologic therapies utilized for moderate-to-severe plaque psoriasis. The findings were organized into sections for each drug: oral acitretin, methotrexate, cyclosporine, apremilast, tofacitinib, and deucravacitinib.Expert opinion: Some psoriasis patients may not respond to initial therapy. Ongoing research is evaluating genetic polymorphisms that may predict an improved response to specific medications. However, financial and insurance barriers, as well as limited genetic polymorphisms correlated with treatment response, may restrict the implementation of genetic testing necessary to personalize treatments. How well psoriasis patients adhere to treatment may contribute greatly to variation in response. Therapeutic drug monitoring may help patients adhere to treatment, improve clinical response, and sustain disease control.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"249-262"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140290008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can we optimize the use of methotrexate to treat pediatric patients with inflammatory skin diseases? 如何优化使用甲氨蝶呤治疗儿科炎症性皮肤病患者？

Expert opinion on drug metabolism & toxicology Pub Date : 2024-03-01 Epub Date: 2024-03-04 DOI: 10.1080/17425255.2024.2326245

Kajetan Kiełbowski, Estera Bakinowska, Andrzej Pawlik

{"title":"How can we optimize the use of methotrexate to treat pediatric patients with inflammatory skin diseases?","authors":"Kajetan Kiełbowski, Estera Bakinowska, Andrzej Pawlik","doi":"10.1080/17425255.2024.2326245","DOIUrl":"10.1080/17425255.2024.2326245","url":null,"abstract":"Introduction: Methotrexate (MTX) is a folic acid antagonist used in clinical practice in oncology and rheumatology, as well as in the treatment of inflammatory skin conditions in children. The low-doses of MTX are commonly used in children for the treatment of many inflammatory and autoimmune conditions, including inflammatory skin diseases, due to its anti-inflammatory and immunomodulatory effects.Areas covered: This review discusses the possibilities for optimizing the use of methotrexate in the treatment of pediatric patients with inflammatory skin diseases. A thorough search through PubMed and Embase databases was performed to identify relevant literature.Expert opinion: Clinical observations confirm the high efficacy and safety of low-dose MTX in children with inflammatory skin diseases. Unfortunately, to date there are few studies providing guidelines on the optimal dosage of MTX in children with inflammatory skin diseases; routes of administration; principles of monitoring; and the safety of long-term use of this medication in children. There is still a need for specific recommendations on the safest and most effective dosing and monitoring regimen for children treated with methotrexate for inflammatory skin diseases.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"111-118"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140013797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive update on the ADMET considerations for α2δ calcium channel ligand medications for treating restless legs syndrome. 关于α2δ钙通道韧带药物治疗无腿症的 ADMET 考虑因素的综合更新。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-03-01 Epub Date: 2024-03-15 DOI: 10.1080/17425255.2024.2329738

Gaia Pellitteri, Salvatore Versace, Giovanni Merlino, Annacarmen Nilo, Gian Luigi Gigli, Mariarosaria Valente

{"title":"A comprehensive update on the ADMET considerations for α2δ calcium channel ligand medications for treating restless legs syndrome.","authors":"Gaia Pellitteri, Salvatore Versace, Giovanni Merlino, Annacarmen Nilo, Gian Luigi Gigli, Mariarosaria Valente","doi":"10.1080/17425255.2024.2329738","DOIUrl":"10.1080/17425255.2024.2329738","url":null,"abstract":"Introduction: Restless legs syndrome/Willis-Ekbom disease (RLS/WED) is a sleep-related sensory-motor disorder associated with poor sleep quality and impaired daily functioning. In patients affected by chronic RLS/WED, a pharmacological therapy is recommended. International guidelines suggest to start the treatment with a α2δ calcium channel ligand in most cases, unless contraindicated.Areas covered: The present review is based on an extensive Internet and PubMed search from 1986 to 2024. Our purpose is to describe the absorption, distribution, metabolism, and toxicology (ADMET) of the α2δ ligands, with common consideration for the therapeutic class, specificities of different compounds, efficacy, and safety in relation to other treatment options.Expert opinion: α2δ ligands are quite similar in their ADMET profiles, sharing most of the pharmacokinetics and potential adverse effects. However, we highlight the linear kinetic of gabapentin enacarbil and pregabalin, differently from gabapentin. α2δ ligands are safe and effective for the treatment of RLS/WED. Additional benefits can be obtained in comorbid insomnia, chronic pain syndromes, history of impulse control disorder, and comorbid anxiety. The use of α2δ ligands is associated with poor risk of augmentation. We still need new long-term safe and effective treatments, which could be developed along with our knowledge of RLS/WED pathophysiology.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"133-142"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140121636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is the impact of metabolic dysfunction-associated steatotic liver disease on drug transport and metabolism? 与脂肪肝相关的代谢功能障碍对药物转运和代谢有何影响？

Expert opinion on drug metabolism & toxicology Pub Date : 2024-03-01 Epub Date: 2024-03-04 DOI: 10.1080/17425255.2024.2324015

Christoph G Dietrich, Andreas Geier

引用次数: 0

Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase. 儿童服用新型抗癫痫药物的肝毒性：VigiBase 的概述和比例失调分析。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-03-01 Epub Date: 2024-02-28 DOI: 10.1080/17425255.2024.2322114

Sanja Petrović, Milena Kovačević, Sandra Vezmar Kovačević, Branislava Miljković

{"title":"Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase.","authors":"Sanja Petrović, Milena Kovačević, Sandra Vezmar Kovačević, Branislava Miljković","doi":"10.1080/17425255.2024.2322114","DOIUrl":"10.1080/17425255.2024.2322114","url":null,"abstract":"Background: We aimed to characterize newer antiseizure medications (ASMs)-induced hepatotoxicity in children and identify signals of disproportionate reporting of hepatotoxicity-related adverse drug events (ADEs).Research design and methods: Case reports reported to VigiBase were accessed using Empirica™ Signal software. To summarize characteristics of the retrieved cases, descriptive statistics were used. A disproportionality analysis was conducted using the Multi-item Gamma Poisson Shrinker algorithm, which calculates Empirical Bayesian Geometric Mean value and its lower and upper 95% confidence limits (EB05 and EB95, respectively). EB05 > 2, N > 0 was considered a signal.Results: Based on 870 analyzed cases, a higher proportion of cases was reported in girls than in boys and in patients aged 2-11 years than in other age groups. Most cases were serious. In 25 cases, hepatotoxicity resulted in death. A high proportion of patients (n = 275, 31.61%) experienced hypersensitivity reactions, mostly due to lamotrigine. The disproportionality analysis yielded 17 signals concerning felbamate, lamotrigine, levetiracetam, oxcarbazepine, stiripentol, and topiramate. Four signals were for severe liver injury and concerned felbamate, lamotrigine, levetiracetam, and topiramate. Gender-biased reporting frequency was detected for four ASM-ADE combinations.Conclusion: Our results should serve to raise clinicians' awareness about the potential association between several newer ASMs and drug-induced liver injury in children.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"165-173"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139914329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cannabidiol: metabolism and clinical efficacy in epileptic patients. 大麻二酚：癫痫患者的代谢和临床疗效。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-03-01 Epub Date: 2024-03-12 DOI: 10.1080/17425255.2024.2329733

Giovanni Battista Dell'Isola, Alberto Verrotti, Miriam Sciaccaluga, Gianluca Dini, Pietro Ferrara, Lucilla Parnetti, Cinzia Costa

{"title":"Cannabidiol: metabolism and clinical efficacy in epileptic patients.","authors":"Giovanni Battista Dell'Isola, Alberto Verrotti, Miriam Sciaccaluga, Gianluca Dini, Pietro Ferrara, Lucilla Parnetti, Cinzia Costa","doi":"10.1080/17425255.2024.2329733","DOIUrl":"10.1080/17425255.2024.2329733","url":null,"abstract":"Introduction: The landscape of epilepsy treatment has undergone a significant transformation with the emergence of cannabidiol as a potential therapeutic agent. Epidiolex, a pharmaceutical formulation of highly purified CBD, garnered significant attention not just for its therapeutic potential but also for being the first cannabis-derived medication to obtain approval from regulatory bodies.Area covered: In this narrative review the authors explore the intricate landscape of CBD as an antiseizure medication, deepening into its pharmacological mechanisms and clinical trials involving various epileptic encephalopathies. This exploration serves as a comprehensive guide, shedding light on a compound that holds promise for individuals contending with the significant challenges of drug-resistant epilepsy.Expert opinion: Rigorous studies highlight cannabidiol's efficacy, safety profile, and potential cognitive benefits, warranting further exploration for its approval in various drug-resistant epilepsy forms. As a promising therapeutic option, cannabidiol not only demonstrates efficacy in seizure control but also holds the potential for broader enhancements in the quality of life, especially for patients with epileptic encephalopathies.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"119-131"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug interactions of carbonic anhydrase inhibitors and activators. 碳酸酐酶抑制剂和激活剂的药物相互作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-03-01 Epub Date: 2024-03-11 DOI: 10.1080/17425255.2024.2328152

Claudiu T Supuran

{"title":"Drug interactions of carbonic anhydrase inhibitors and activators.","authors":"Claudiu T Supuran","doi":"10.1080/17425255.2024.2328152","DOIUrl":"10.1080/17425255.2024.2328152","url":null,"abstract":"Introduction: Carbonic anhydrases (CAs, EC 4.2.1.1) have been established drug targets for decades, with their inhibitors and activators possessing relevant pharmacological activity and applications in various fields. At least 11 sulfonamides/sulfamates are clinically used as diuretics, antiglaucoma, antiepileptic, or antiobesity agents and one derivative, SLC-0111, is in clinical trials as antitumor/antimetastatic agent. The activators were less investigated with no clinically used agent.Areas covered: Drug interactions between CA inhibitors/activators and various other agents are reviewed in publications from the period March 2020 - January 2024.Expert opinion: Drug interactions involving these agents revealed several interesting findings. Acetazolamide plus loop diuretics is highy effective in acute decompensated heart failure, whereas ocular diseases such as X-linked retinoschisis and macular edema were treated by acetazolamide plus bevacizumab or topical NSAIDs. Potent anti-infective effects of acetazolamide and other CAIs, alone or in combination with other agents were demonstrated for the management of Neisseria gonorrhoea, vancomycin resistant enterococci, Acanthamoeba castellanii, Trichinella spiralis, and Cryptococcus neoformans infections. Topiramate, in combination with phentermine is incresingly used for the management of obesity, whereas zonisamide plus levodopa is highly effective for Parkinson's disease. Acetazolamide, methazolamide, ethoxzolamide, and SLC-0111 showed synergistic antitumor/antimetastatic action in combination with many other antitumor drugs.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"143-155"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer. 用于治疗乳腺癌患者的抗体药物共轭物的药代动力学和药效学。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-01-01 Epub Date: 2024-01-12 DOI: 10.1080/17425255.2024.2302460

François Cherifi, Angélique Da Silva, Diogo Martins-Branco, Ahmad Awada, Guilherme Nader-Marta

{"title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer.","authors":"François Cherifi, Angélique Da Silva, Diogo Martins-Branco, Ahmad Awada, Guilherme Nader-Marta","doi":"10.1080/17425255.2024.2302460","DOIUrl":"10.1080/17425255.2024.2302460","url":null,"abstract":"Introduction: Currently three antibody-drug-conjugates (ADC) are approved by the European Medicines Agency (EMA) for treatment of breast cancer (BC) patient: trastuzumab-emtansine, trastuzumab-deruxtecan and sacituzumab-govitecan. ADC are composed of a monoclonal antibody (mAb) targeting a specific antigen, a cytotoxic payload and a linker. Pharmacokinetics (PK) and pharmacodynamics (PD) distinguish ADC from conventional chemotherapy and must be understood by clinicians.Areas covered: Our review delineates the PK/PD profiles of ADC approved for the treatment of BC with insight for future development. This is an expert opinion literature review based on the EMA's Assessment Reports, enriched by a comprehensive literature search performed on Medline in August 2023.Expert opinion: All three ADC distributions are described by a two-compartment structure: tissue and serum. Payload concentration peak is immediate but remains at low concentration. The distribution varied for all ADC only with body weight. mAb will be metabolised firstly by the saturable complex formation of ADC/Tumour-Receptor and secondly by binding of FcgRs in immune cells. They are all excreted in the bile and faeces with minimal urine elimination. Dose adjustments, apart from weight, are not recommended. Novel ADC are composed of cleavable linkers with various targets/payloads with the same PK/PD properties, but novel structures of ADC are in development.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"45-59"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139428092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interindividual variability in statin pharmacokinetics and effects of drug transporters. 他汀类药物药代动力学的个体间差异和药物转运体的影响。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI: 10.1080/17425255.2024.2305746

Takeshi Hirota, Ichiro Ieiri

{"title":"Interindividual variability in statin pharmacokinetics and effects of drug transporters.","authors":"Takeshi Hirota, Ichiro Ieiri","doi":"10.1080/17425255.2024.2305746","DOIUrl":"10.1080/17425255.2024.2305746","url":null,"abstract":"Introduction: Statins are HMG-CoA reductase inhibitors that primarily lower plasma cholesterol levels. It has been suggested that the myotoxic response is a direct result of hydroxymethylglutaryl-CoA reductase inhibition and dose-dependent. Therefore, an accurate understanding of the combination of drugs that inhibit statin metabolism and factors that cause interindividual variability in the pharmacokinetics of statin is important to avoid serious side effects of statins. Relevant articles included in this review were identified through a PubMed search (through May 2023).Areas covered: This review provides an overview of hepatic and intestinal metabolism of statins, followed by a discussion of drug-drug interactions and interindividual variables that influence statin pharmacokinetics: gut bacteria, disease, and pharmacokinetics-related genetic polymorphisms.Expert opinion: Drug-drug interactions have a strong influence on statin pharmacokinetics, and gut microbiota, disease, and genetic polymorphisms all contribute significantly to interindividual variation in statin pharmacokinetics. Individual optimization of statin treatment requires studies that consider the progression of the disease and associated changes in concomitant medications.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"37-43"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0